Platelet‐activating factor antagonist‐based intensive antiplatelet strategy in acute ischemic stroke: A propensity score matched with network pharmacology analysis

Author:

Han Xiaoyan12,Li Youjia1,Chen Xuemin3,Pan Dong2,Mo Junning1,Qiu Jiaming1,Li Yi2,Chen Yan1,Huang Yan1,Shen Qingyu2,Tang Yamei245ORCID

Affiliation:

1. Department of Neurology First People's Hospital of Zhaoqing Zhaoqing People's Republic of China

2. Department of Neurology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou People's Republic of China

3. Guangdong Medical University Zhanjiang People's Republic of China

4. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou People's Republic of China

5. Guangdong Province Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine Sun Yat‐Sen University Guangzhou People's Republic of China

Abstract

AbstractBackgroundDiterpene ginkgolides meglumine injection (DGMI) is a platelet‐activating factor receptor (PAFR) antagonist that can be used to treat acute ischemic stroke (AIS). This study evaluated the efficacy and safety of an intensive antiplatelet strategy based on PAFR antagonists and explored the underlying mechanisms of PAFR antagonists in AIS treatment.MethodsThis is a retrospective study applying propensity score methods to match AIS patients treated with DGMI to nontreated patients. The primary outcome was functional independence (modified Rankin Scale [mRS] 0–2) at 90 days. The safety outcome was bleeding risk. We used McNemar test to compare the efficacy outcome. Subsequently, the network pharmacology analysis was performed.Results161 AIS patients treated with DGMI in the study were matched with 161 untreated patients. Compared with untreated patients, DGMI‐treated patients had a significantly higher rate of mRS ranking 0–2 at 90 days (82.0% vs. 75.8%, p < 0.001), without increased risk of bleeding. The gene enrichment analysis showed that the overlap genes of DGMI targeted and AIS‐related enriched in thrombosis and inflammatory‐related signaling pathways.ConclusionsAn intensive antiplatelet strategy of DGMI plus traditional antiplatelet agents is effective in treating AIS and may work by mediating post‐stroke inflammation and thrombosis.

Funder

Guangzhou Municipal Science and Technology Project

Guangdong Medical Research Foundation

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Pharmacology (medical),Physiology (medical),Psychiatry and Mental health,Pharmacology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3